Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Lee

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Cancer Journal (Sudbury, Mass.)|May 29, 2019
Management of T-Cell Engaging Immunotherapy ComplicationsIndumathy Varadarajan, Daniel W Lee
Current Opinion in Hematology|September 4, 2015
Paving the road ahead for CD19 CAR T-cell therapyAnandani Nellan, Daniel W Lee
Cancer Journal (Sudbury, Mass.)|March 22, 2021
Cytokine Release Syndrome Biology and ManagementDustin A Cobb, Daniel W Lee
Regulatory Peptides|May 6, 2008
The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J miceDaniel W Lee, Matthew C Leinung, Patricia Grasso
Regulatory Peptides|December 23, 2009
Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administrationDaniel W Lee, Matthew C Leinung, Patricia Grasso
Frontiers in Oncology|May 31, 2012
Immunotherapy targets in pediatric cancerRimas J Orentas, Daniel W Lee, Crystal Mackall
Annual Review of Medicine|January 27, 2026
CAR T Cell Toxicities and Emerging Treatment StrategiesAmanda M Lulu, Erica Steele, Daniel W Lee
Therapeutics and Clinical Risk Management|March 19, 2019
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapyLara L Riegler, Gavin P Jones, Daniel W Lee
Current Hematologic Malignancy Reports|August 19, 2018
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory DiseaseKatherine C Pehlivan, Brynn B Duncan, Daniel W Lee
Regulatory Peptides|April 7, 2009
Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systemsZachary M Novakovic, Matthew C Leinung, Daniel W Lee, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Cancer Journal (Sudbury, Mass.)|May 29, 2019
Management of T-Cell Engaging Immunotherapy ComplicationsIndumathy Varadarajan, Daniel W Lee
Current Opinion in Hematology|September 4, 2015
Paving the road ahead for CD19 CAR T-cell therapyAnandani Nellan, Daniel W Lee
Cancer Journal (Sudbury, Mass.)|March 22, 2021
Cytokine Release Syndrome Biology and ManagementDustin A Cobb, Daniel W Lee
Regulatory Peptides|May 6, 2008
The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J miceDaniel W Lee, Matthew C Leinung, Patricia Grasso
Regulatory Peptides|December 23, 2009
Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administrationDaniel W Lee, Matthew C Leinung, Patricia Grasso
Frontiers in Oncology|May 31, 2012
Immunotherapy targets in pediatric cancerRimas J Orentas, Daniel W Lee, Crystal Mackall
Annual Review of Medicine|January 27, 2026
CAR T Cell Toxicities and Emerging Treatment StrategiesAmanda M Lulu, Erica Steele, Daniel W Lee
Therapeutics and Clinical Risk Management|March 19, 2019
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapyLara L Riegler, Gavin P Jones, Daniel W Lee
Current Hematologic Malignancy Reports|August 19, 2018
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory DiseaseKatherine C Pehlivan, Brynn B Duncan, Daniel W Lee
Regulatory Peptides|April 7, 2009
Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systemsZachary M Novakovic, Matthew C Leinung, Daniel W Lee, et al.
Pageof 6